Aliso Viejo, CA, Jan. 10, 2018 -- OrthAlign, Inc., a leading provider of orthopedic surgical navigation solutions, announced today that Dr. Steven Haas, Chief of the Knee Service at Hospital for Special Surgery in New York, NY, has joined the company’s Executive Surgeon Council (“ESC”) advisory board.
|
|||
The ESC works closely with OrthAlign’s management team and product development group, bringing innovative products to market built upon proprietary, sensor-based surgical navigation technologies. The company’s flagship product, KneeAlign®, uses instrument-mounted sensor navigation to provide real-time guidance during primary total knee replacement procedures. OrthAlign launched UniAlign™ in early 2017, bringing the accuracy and consistency of KneeAlign to partial knee replacement surgery, opening opportunities for customers to bring impactful computer navigation into surgery centers.
“We are so pleased to have Dr. Haas join our very talented and engaged board of surgeon advisors, and to bring with him his wealth of experience and history of innovation in this space,” commented Eric B. Timko, Chairman and CEO of OrthAlign. “As we continue to expand our platform of indications, we look forward to evolving KneeAlign and building a suite of applications that make OrthAlign’s technologies the go-to solution for their ease of use, economics, and clinical results.”
"I am excited to join OrthAlign’s outstanding clinical and management teams as they continue to expand and more broadly apply their proven sensor technology,” said Dr. Steven Haas. “OrthAlign has innovative products, and I look forward to working with them as they expand their platform."
Dr. Haas speaks nationally and internationally on hip and knee topics, and has contributed more than 90 publications into orthopedic literature. He is well known for development of ground-breaking surgical technique and instrumentation for performing minimally invasive knee replacement; along with development of high performance knee replacement systems. Dr. Haas received his education and training at Harvard, Cornell and the University of Rochester.
ORTHALIGN, INC.
OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit www.orthalign.com or contact Adam Simone ([email protected]).
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/070ff4f7-3771-4d0f-a87d-d457737c24c1
Adam Simone OrthAlign [email protected]


Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



